title: Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.
abstract: Biopharmaceuticals, monoclonal antibody (mAb)-based therapeutics in particular, have positively impacted millions of lives. MAbs and related therapeutics are highly desirable from a biopharmaceutical perspective as they are highly target specific and well tolerated within the human system. Nevertheless, several mAbs have been discontinued or withdrawn based either on their inability to demonstrate efficacy and/or due to adverse effects. Approved monoclonal antibodies and derived therapeutics have been associated with adverse effects such as immunogenicity, cytokine release syndrome, progressive multifocal leukoencephalopathy, intravascular haemolysis, cardiac arrhythmias, abnormal liver function, gastrointestinal perforation, bronchospasm, intraocular inflammation, urticaria, nephritis, neuropathy, birth defects, fever and cough to name a few. The advances made in this field are also impeded by a lack of progress in bioprocess development strategies as well as increasing costs owing to attrition, wherein the lack of efficacy and safety accounts for nearly 60 % of all factors contributing to attrition. This reiterates the need for smarter preclinical development using quality by design-based approaches encompassing carefully designed predictive models during early stages of drug development. Different in vitro and in silico methods are extensively used for predicting biological activity as well as toxicity during small molecule drug development; however, their full potential has not been utilized for biological drug development. The scope of in vitro and in silico tools in early developmental stages of monoclonal antibody-based therapeutics production and how it contributes to lower attrition rates leading to faster development of potential drug candidates has been evaluated. The applicability of computational toxicology approaches in this context as well as the pitfalls and promises of extending such techniques to biopharmaceutical development has been highlighted.
authors.affiliation: Chemical Engineering and Advanced Materials, Newcastle University, Newcastle upon Tyne, NE17RU, UK. arathi.kizhedath@newcastle.ac.uk.|Medical Toxicology Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4AA, UK. arathi.kizhedath@newcastle.ac.uk.
authors.forename: Arathi
authors.identifier: http://orcid.org/0000-0002-6939-6416
authors.initials: A
authors.lastname: Kizhedath
authors.affiliation: Medical Toxicology Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4AA, UK.
authors.forename: Simon
authors.initials: S
authors.lastname: Wilkinson
authors.affiliation: Chemical Engineering and Advanced Materials, Newcastle University, Newcastle upon Tyne, NE17RU, UK.
authors.forename: Jarka
authors.initials: J
authors.lastname: Glassey
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D003198:Computer Simulation; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D008954:Models, Biological; D018675:Toxicity Tests / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal
keywords: In vitro and in silico tools; Monoclonal antibody-based therapeutics; Predictive toxicology; QSAR; Safety pharmacology